DOCSLIB.ORG

07-101 Phrma NM Heart

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

200R9ep ort M EDICINES IN D EVELOPMENT FOR Heart Disease and Stroke PRESENTED BY AMERICA ’ S PHARMACEUTICAL RESEARCH COMPANIES More Than 300 Medicines in Testing for Two Leading Causes of Death in Americans harmaceutical and biotechnology researchers are MEDICINES IN DEVELOPMENT FOR HEART DISEASE AND STROKE * working on 312 medicines for two of the three Pleading causes of death in Americans—heart disease Acute Coronary Syndrome 21 and stroke—keeping up the momentum of drug discovery Adjunctive Therapies 5 Angina 2 that has helped cut deaths from these diseases by more Arrhythmia/Atrial Fibrillation 20 than a quarter between 1999 and 2005. All of the medicines Atherosclerosis 18 are either in clinical trials or awaiting approval by the Coronary Artery Disease 11 Heart Attack 16 Food and Drug Administration. Heart Failure 33 Hypertension 36 According to the National Center for Health Statistics, Imaging Agents 10 heart disease has topped the list of killer diseases every Ischemic Disorders 18 Lipid Disorders 26 year but one since 1900. (The exception was 1918, Peripheral Vascular Disease 27 when an influenza epidemic killed more than 450,000 Pulmonary Vascular Disease 16 Stroke Americans.) In 2002, cancer surpassed heart disease as 22 Thrombosis 40 the top killer of Americans under age 85, who account Other 39 for 98.4 percent of the U.S. population. Stroke is the *S ome medicines are listed in more than one category. third leading cause of death. Thanks in large part to new drug treatments, death rates cost of these diseases to American society is more than from heart disease and stroke are falling. According to the $448 billion a year. National Heart, Lung and Blood Institute (NHLBI), if death The medicines in development include 36 for high rates were the same as those of 30 years ago, 815,000 blood pressure, 33 for heart failure, 16 for heart attacks, more Americans would die of heart disease annually and and 22 for stroke. Many of the potential medicines use 250,000 more would die of stroke. This reduction in cutting-edge technologies and new scientific approaches. death rates is “one of the great triumphs of medicine in For example: the past 50 years,” according to cardiologist Dr. Eugene Braunwald of Brigham and Women’s Hospital at • Human stem cells that may restore cardiac function by Harvard University. forming new heart muscle. Much of the progress is due to the development of • A new anticoagulant that regulates clot formation to effective medicines to control both blood pressure and prevent deep vein thrombosis. cholesterol, according to officials at the NHLBI. In • A gene therapy that uses a patient’s own cells to treat addition, treatment of heart attacks has vastly improved. heart failure. Twenty-five years ago, the treatment for heart attacks was simply bed rest. Today, doctors have medicines that can These new medicines promise to continue the already stop a heart attack in mid-stream as well as other high- remarkable progress against heart disease and stroke and tech treatments. to raise the quality of life for patients suffering from these diseases. But, experts warn, the war against heart disease and stroke is not yet won. According to the American Heart Association, every 37 seconds an American dies of cardiovascular disease, and nearly 80 million Americans have one or more types of cardiovascular disease. Many Billy Tauzin people who survive heart attacks develop heart failure, a President and CEO chronic disease that affects 5.3 million Americans. The PhRMA Medicines in Development for Heart Disease and Stroke A CUTE C ORONARY S YNDROME Product Name Sponsor Indication Development Status* Angiomax ® The Medicines Company acute coronary syndrome application submitted bivalirudin Parsippany, NJ (973) 656-1616 apixaban Bristol-Myers Squibb acute coronary syndrome Phase III (factor XA Princeton, NJ (see also stroke, thrombosis) (212) 546-4000 inhibitor) Pfizer (860) 732-5156 New York, NY Arixtra ® GlaxoSmithKline acute coronary syndrome application submitted fondaparinux Rsch. Triangle Park, NC (888) 825-5249 cangrelor The Medicines Company acute coronary syndrome Phase III Parsippany, NJ (800) 388-1183 DX9065a Daiichi Sankyo acute coronary syndrome Phase II Parsippany, NJ (see also coronary artery disease, (973) 359-2600 thrombosis) E5555 Eisai Medical Research acute coronary syndrome/chronic Phase II Ridgefield Park, NJ atherothrombotic disease (888) 422-4743 factor IIa/Xa Bayer HealthCare acute coronary syndrome Phase I inhibitor Pharmaceuticals (888) 842-2937 Wayne, NJ Integrelin ® Schering-Plough early acute coronary syndrome Phase III eptifibatide Kenilworth, NJ (908) 298-4000 M118 Momenta Pharmaceuticals acute coronary syndrome Phase II Cambridge, MA (617) 491-9700 otamixaban sanofi-aventis acute coronary syndrome Phase II (XRP0673) Bridgewater, NJ (800) 633-1610 prasugrel Eli Lilly acute coronary syndrome application submitted (CS-747) Indianapolis, IN (800) 545-5979 Daiichi Sankyo (973) 359-2600 Parsippany, NJ -------------------------------------------------------------------------------------- acute coronary syndrome Phase II (combination therapy) (800) 545-5979 (973) 359-2600 PRT060128 Portola Pharmaceuticals acute coronary syndrome Phase II South San Francisco, CA (see also heart attack) rivaroxaban Bayer HealthCare acute coronary syndrome Phase II Pharmaceuticals (see also stroke, thrombosis) (888) 842-2937 Wayne, NJ Johnson & Johnson Pharmaceutical Reseach & Development Raritan, NJ SCH-530348 Schering-Plough acute coronary syndrome Phase III Kenilworth,NJ (908) 298-4000 * For more information about a specific medicine in this report, please call the telephone number listed. 2 M EDICINES IN D EVELOPMENT FOR Heart Disease and Stroke 2009 A CUTE C ORONARY S YNDROME Product Name Sponsor Indication Development Status TAK-442 Takeda Pharmaceuticals acute coronary syndrome Phase II North America (see also thrombosis) (877) 582-5332 Deerfield, IL Thelin ™ Encysive Pharmaceuticals acute coronary disorders Phase I sitaxentan Houston, TX (see also heart failure, (713) 796-8822 pulmonary vascular disease) ticagrelor AstraZeneca acute coronary syndrome Phase III Wilmington, DE (see also thrombosis) (800) 236-9933 varespladib Anthera Pharmaceuticals acute coronary syndrome Phase II San Mateo, CA (see also atherosclerosis) (510) 277-0356 VIA-2291 VIA Pharmaceuticals acute coronary syndrome Phase II San Francisco, CA (see also atherosclerosis) (415) 283-2200 VT-111 Viron Therapeutics acute coronary syndrome Phase II London, ON (see also atherosclerosis, (519) 858-5109 coronary artery disease) Vytorin ™ Merck acute coronary syndrome Phase III ezetimibe/ Whitehouse Station, NJ (800) 672-6372 simvastatin Schering-Plough (908) 298-4000 Kenilworth, NJ A DJUNCTIVE T HERAPIES ; R EVASCULARIZATION Product Name Sponsor Indication Development Status CCX140 ChemoCentryx treatment of vascular restinosis Phase I Mountain View, CA following angioplasty or stenting (650) 210-2900 fibrin patch Omrix Biopharmaceuticals surgical blood loss Phase II New York, NY (212) 887-6500 Ethicon, a Johnson & Johnson Company Somerville, NJ NovoSeven ® Novo Nordisk post-operative hemorrhage in Phase II eptacog alfa Princeton, NJ cardiac surgery (800) 727-6500 rFXIII Novo Nordisk post-operative hemorrhage in Phase I Princeton, NJ cardiac surgery (800) 727-6500 Trinam ® Ark Therapeutics prevention of vascular restinosis Phase III (EG004) London, England following vascular graft surgery A NGINA Product Name Sponsor Indication Development Status ACCLAIM ™ Angiogenix angina pectoris Phase II isosorbide Burlingame, CA (650) 579-6685 mononitrate/ arginine M EDICINES IN D EVELOPMENT FOR Heart Disease and Stroke 2009 3 A NGINA Product Name Sponsor Indication Development Status FGF-1 CardioVascular angina pectoris Phase II (fibroblast growth BioTherapeutics (see also peripheral vascular disease) (702) 248-1174 factor 1) Las Vegas, NV A RRHYTHMIA , A TRIAL F IBRILLATION Product Name Sponsor Indication Development Status Amio-Aqueous ™ Academic Pharmaceuticals supraventricular arrhythmia, Phase III aqueous Lake Bluff, IL ventricular tachycardia (847) 735-1170 amiodarone ATI-2042 ARYx Therapeutics atrial fibrillation Phase II Fremont, CA (510) 585-2200 ATPace ™ Duska Therapeutics diagnosis of bradycardia, Phase II adenosine La Jolla, CA treatment of paroxysmal (858) 551-5700 triphosphate supraventricular tachycardia injection Avapro ® sanofi-aventis atrial fibrillation Phase III irbesartan Bridgewater, NJ (see also heart failure) (800) 633-1610 AZD1305 AstraZeneca atrial fibrillation, left ventricular Phase II Wilmington, DE dysfunction (800) 236-9933 -------------------------------------------------------------------------------------- atrial flutter Phase I/II (800) 236-9933 -------------------------------------------------------------------------------------- arrhythmia Phase I (800) 236-9933 capadenoson Bayer HealthCare atrial fibrillation Phase II Pharmaceuticals (888) 842-2937 Wayne, NJ celivarone sanofi-aventis atrial fibrillation Phase II (SSR149744) Bridgewater, NJ (800) 633-1610 GAP-134 Wyeth Pharmaceuticals arrhythmia Phase I Collegeville, PA (800) 934-5556 idrabiotaparinux sanofi-aventis atrial fibrillation Phase III Bridgewater, NJ (see also thrombosis) (800) 633-1610 idraparinux sanofi-aventis atrial fibrillation Phase III Bridgewater, NJ (see also thrombosis) (800) 633-1610 Lipitor ® Pfizer atrial fibrillation Phase II/III atorvastatin New York, NY (860) 732-5156 Lovaza ® GlaxoSmithKline atrial fibrillation Phase III omega-3 ethylester
Recommended publications
  • WHO Drug Information Vol. 20, No. 3, 2006

    WHO Drug Information Vol. 20, No. 3, 2006

    WHO DRUG INFORMATION VOLUME 20• NUMBER 3 • 2006 RECOMMENDED INN LIST 56 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA WHO Drug Information Vol 20, No. 3, 2006 World Health Organization WHO Drug Information Contents Biomedicines and Vaccines Counterfeit taskforce launched 192 Fake artesunate warning sheet 193 Monoclonal antibodies: a special Resolution on counterfeiting 193 regulatory challenge? 165 Improving world health through regulation of biologicals 173 Regulatory Action and News Influenza virus vaccines for 2006–2007 Safety and Efficacy Issues northern hemisphere 196 Trastuzumab approved for primary Global progress in monitoring immuniza- breast cancer 196 tion adverse events 180 Emergency contraception over-the- Intracranial haemorrhage in patients counter 197 receiving tipranavir 180 Ocular Fusarium infections: ReNu Infliximab: hepatosplenic T cell MoistureLoc® voluntary withdrawal 197 lymphoma 181 Saquinavir: withdrawal of soft gel Lamotrigine: increased risk of non- capsule Fortovase® 197 syndromic oral clefts 181 Latest list of prequalified products and Biphosphonates: osteonecrosis of manufacturers 198 the jaw 181 Clopidogrel: new medical use 199 Enoxaparin dosage in chronic kidney Dronedarone: withdrawal of marketing disease 182 authorization 199 Terbinafine and life-threatening blood dyscrasias 183 Adverse reactions in children: why Recent Publications, report? 183 Hepatitis B reactivation and anti-TNF- Information and Events alpha agents 185 MSF issues ninth antiretroviral
  • Metabolic Enzyme/Protease

    Metabolic Enzyme/Protease

    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Metabolic Enzyme/Protease Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. In each pathway, enzymes catalyze the conversion of substrates into structurally similar products. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation. Metabolism maintains the living state of the cells and the organism. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. Proteases can not only activate proteins such as cytokines, or inactivate them such as numerous repair proteins during apoptosis, but also expose cryptic sites, such as occurs with β-secretase during amyloid precursor protein processing, shed various transmembrane proteins such as occurs with metalloproteases and cysteine proteases, or convert receptor agonists into antagonists and vice versa such as chemokine conversions carried out by metalloproteases, dipeptidyl peptidase IV and some cathepsins. In addition to the catalytic domains, a great number of proteases contain numerous additional domains or modules that substantially increase the complexity of their functions.
  • Serpins in Hemostasis As Therapeutic Targets for Bleeding Or Thrombotic Disorders

    Serpins in Hemostasis As Therapeutic Targets for Bleeding Or Thrombotic Disorders

    MINI REVIEW published: 07 January 2021 doi: 10.3389/fcvm.2020.622778 Serpins in Hemostasis as Therapeutic Targets for Bleeding or Thrombotic Disorders Elsa P. Bianchini 1*, Claire Auditeau 1, Mahita Razanakolona 1, Marc Vasse 1,2 and Delphine Borgel 1,3 1 HITh, UMR_S1176, Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay, Le Kremlin-Bicêtre, France, 2 Service de Biologie Clinique, Hôpital Foch, Suresnes, France, 3 Laboratoire d’Hématologie Biologique, Hôpital Necker, APHP, Paris, France Edited by: Bleeding and thrombotic disorders result from imbalances in coagulation or fibrinolysis, Marie-Christine Bouton, respectively. Inhibitors from the serine protease inhibitor (serpin) family have a key role Institut National de la Santé et de la in regulating these physiological events, and thus stand out as potential therapeutic Recherche Médicale (INSERM), France targets for modulating fibrin clot formation or dismantling. Here, we review the diversity Reviewed by: of serpin-targeting strategies in the area of hemostasis, and detail the suggested use of Xin Huang, modified serpins and serpin inhibitors (ranging from small-molecule drugs to antibodies) University of Illinois at Chicago, United States to treat or prevent bleeding or thrombosis. Martine Jandrot-Perrus, Keywords: serpin (serine proteinase inhibitor), antithrombin (AT), protein Z-dependent protease inhibitor (ZPI), Institut National de la Santé et de la plasminogen activator inhibitor 1 (PAI-1), therapy, protease nexin I (PN-1) Recherche Médicale (INSERM), France *Correspondence: INTRODUCTION Elsa P. Bianchini elsa.bianchini@ universite-paris-saclay.fr Coagulation (the formation of a solid fibrin clot at the site of vessel injury, to stop bleeding) and fibrinolysis (the disaggregation of a clot, to prevent the obstruction of blood flow) are Specialty section: interconnected pathways that both help to maintain the hemostatic balance.
  • Metabolic Disease

    Metabolic Disease

    Metabolic Disease Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models. www.MedChemExpress.com 1 Metabolic Disease Inhibitors & Modulators (-)-(S)-Equol (-)-Fucose Cat. No.: HY-100583 (6-Desoxygalactose; L-(-)-Fucose; L-Galactomethylose) Cat. No.: HY-N1480 Bioactivity: (-)-(S)-Equol is a high affinity ligand for estrogen receptor Bioactivity: (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure β with a Ki of 0.73 nM. determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interactions. Purity: 99.82% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg 100 mg (-)-PX20606 trans isomer (24R)-MC 976 ((-)-PX-102 trans isomer; (-)-PX-104) Cat. No.: HY-100443B Cat. No.: HY-15267A Bioactivity: (-)-PX20606 trans isomer is a FXR agonist with EC50s of 18 Bioactivity: (24R)-MC 976 is a Vitamin D3 derivative. and 29 nM for FXR in FRET and M1H assay, respectively.
  • Medicaments Antithrombotiques En Cours De Developpement

    Medicaments Antithrombotiques En Cours De Developpement

    AVERTISSEMENT Ce document est le fruit d'un long travail approuvé par le jury de soutenance et mis à disposition de l'ensemble de la communauté universitaire élargie. Il est soumis à la propriété intellectuelle de l'auteur. Ceci implique une obligation de citation et de référencement lors de l’utilisation de ce document. D'autre part, toute contrefaçon, plagiat, reproduction illicite encourt une poursuite pénale. Contact : [email protected] LIENS Code de la Propriété Intellectuelle. articles L 122. 4 Code de la Propriété Intellectuelle. articles L 335.2- L 335.10 http://www.cfcopies.com/V2/leg/leg_droi.php http://www.culture.gouv.fr/culture/infos-pratiques/droits/protection.htm UNIVERSITE DE LORRAINE 2015 _______________________________________________________________________________ FACULTE DE PHARMACIE T H E S E Présentée et soutenue publiquement le 2 Octobre 2015, sur un sujet dédié aux : NOUVELLES CIBLES DE MEDICAMENTS ANTITHROMBOTIQUES EN COURS DE DEVELOPPEMENT pour obtenir le Diplôme d'Etat de Docteur en Pharmacie par Nicolas BALLOIS né le 29 Août 1989 Membres du Jury Président : Pr. Béatrice FAIVRE Professeur des Universités, Université de Lorraine Juges : Dr. Julien PERRIN Maître de Conférences Universitaire, Université de Lorraine Dr. Michèle MARTIN Assistante Hospitalo-Universitaire, Université de Lorraine Dr. Philippe LADURE Pharmacien, laboratoires PIERRE FABRE UNIVERSITÉ DE LORRAINE FACULTÉ DE PHARMACIE Année universitaire 2014-2015 DOYEN Francine PAULUS Vice-Doyen Béatrice FAIVRE Directeur des
  • Therapeutics Targeting the Fibrinolytic System

    Therapeutics Targeting the Fibrinolytic System

    Lin et al. Experimental & Molecular Medicine (2020) 52:367–379 https://doi.org/10.1038/s12276-020-0397-x Experimental & Molecular Medicine REVIEW ARTICLE Open Access Therapeutics targeting the fibrinolytic system Haili Lin1,LuningXu1,ShujuanYu2, Wanjin Hong3, Mingdong Huang2 and Peng Xu 3 Abstract The function of the fibrinolytic system was first identified to dissolve fibrin to maintain vascular patency. Connections between the fibrinolytic system and many other physiological and pathological processes have been well established. Dysregulation of the fibrinolytic system is closely associated with multiple pathological conditions, including thrombosis, inflammation, cancer progression, and neuropathies. Thus, molecules in the fibrinolytic system are potent therapeutic and diagnostic targets. This review summarizes the currently used agents targeting this system and the development of novel therapeutic strategies in experimental studies. Future directions for the development of modulators of the fibrinolytic system are also discussed. Introduction efficacies than those of the plasminogen activators. The Fibrinolysis is the process of dissolving blood clots, activities of plasminogen activators are modulated by thereby preventing the obstruction of blood vessels. plasminogen activator inhibitor-1 and −2 (PAI-1 and PAI- Triggered by the activation of the fibrinolytic system, 2). As PK serves as an alternative plasminogen activator, its fibrinolysis is mainly regulated by proteases and protease physiological inhibitor, C1 esterase inhibitor, is also named inhibitors. In addition to the originally identified throm- plasminogen activator inhibitor-3 (PAI-3). bolytic function, the fibrinolytic system has also been 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; found to play pivotal roles in various physiological and The Fibrinolytic System pathological processes, e.g., tissue remodeling, immune Plasmin and plasminogen responses, and cancer progression.
  • Mechanisms of Late-Delayed Radiation Induced Brain Injury

    Mechanisms of Late-Delayed Radiation Induced Brain Injury

    MECHANISMS OF LATE-DELAYED RADIATION INDUCED BRAIN INJURY: INSIGHTS FROM EXTRACELLULAR MATRIX AND TRANSCRIPTIONAL PROFILING BY RACHEL N. ANDREWS, D.V.M. A Dissertation Submitted to the Graduate Faculty of WAKE FOREST UNIVERSITY GRADUATE SCHOOL OF ARTS AND SCIENCES in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY Molecular Medicine and Translational Science April 4th 2018 Winston-Salem, North Carolina Approved By: J. Mark Cline, D.V.M., Ph.D., Advisor Linda J. Metheny-Barlow, Ph.D., Chair Gretchen Neigh, Ph.D. Kerry O’Banion, M.D., Ph.D. Ann M. Peiffer, Ph.D. 1 DEDICATION To my father: without your guidance, love, and dogged persistence I would have become a graphic designer and presumably equally in debt. And to my grandfather, a hopeful scientist. I hope I have made you proud. i ACKNOWLEDGEMENTS They say it takes a village to raise a child – it apparently requires no less than four of them to develop a Ph.D. candidate. Although my academic journey has taken me many different places, I am forever grateful to those who have so generously given their time, mentorship, and support which have shaped me into the scientist I am today. I would like to thank the Department of Pathology, Section on Comparative Medicine for providing my research ‘home’ for the last 4 years and for their collegiality and continual emphasis on pursuing research intended to advance our understanding of human health. Above all, I must express my gratitude to my mentor, Dr. Mark Cline. His unwavering support, enthusiasm, and encouragement are what have inspired me to devote my career to translational research.
  • WO 2011/012715 Al

    WO 2011/012715 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 3 February 2011 (03.02.2011) WO 2011/012715 Al (51) International Patent Classification: Heidelberg (DE). KRUSCH, Mathias [DE/DE]; Am A61K 47/10 (2006.01) A61K 9/50 (2006.01) Hungerberg 15, 69434 Hirschhorn (DE). VETTER, Dirk A61K 9/16 (2006.01) A61K 9/10 (2006.01) [DE/DE]; Haydnstr. 9, 69121 Heidelberg (DE). VOIGT, A61K 9/28 (2006.01) Tobias [DE/DE]; Handschuhsheimer Landstr. 9/1, 69120 Heidelberg (DE). (21) International Application Number: PCT/EP20 10/06 1155 (74) Agent: BUCHEL, Edwin; Isenbruck Bδsl Hδrschler LLP, Eastsite One, Seckenheimer Landstrafie 4, 681 63 (22) International Filing Date: Mannheim (DE). 30 July 2010 (30.07.2010) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 09167026.5 31 July 2009 (3 1.07.2009) EP HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 09172339.5 6 October 2009 (06.10.2009) EP KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (71) Applicant (for all designated States except US): AS- ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, CENDIS PHARMA AS [DK/DK]; Tuborg Boulevard NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, 12, DK-2900 Hellerup (DK).